Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,536 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Traumatic Brain Injury
Interventions
nVNS, SOC
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
12 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Recruiting Not applicable Interventional Accepts healthy volunteers

TENS Unit for Analgesia During IUD Insertion

NCT06240260
Conditions
IUD, Analgesia, Patient Preference, Pain, Acute
Interventions
TENS (transcutaneous electrical nerve stimulation) unit, Standard care
Device · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
12 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions
Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
59
States / cities
Mobile, Alabama • San Francisco, California • Stanford, California + 50 more
Conditions
Exercise, Transplantation
Interventions
Exercise program
Other
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
4 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Not applicable Interventional Results available

Dexcom Continuous Glucose Monitoring in Long-term Care

NCT04818242
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Dexcom G6 CGM with GTS, POC Blood Glucose Test + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Atrial Fibrillation, Cognitive Symptom, Executive Dysfunction, Cognitive Change, Cognitive Impairment, Cognitive Impairment, Mild
Interventions
Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm
Other
Lead sponsor
David Brunk, PA-C, MMS
Other
Eligibility
35 Years to 80 Years
Enrollment
600 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Colorado Springs, Colorado
Completed Not applicable Interventional Results available

Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB)

NCT03131960
Conditions
Cerebrovascular Stroke, Upper Extremity Paresis
Interventions
Paired Vagus Nerve Stimulation, Rehabilitation
Device · Other
Lead sponsor
MicroTransponder Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Downey, California • Santa Monica, California + 12 more
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Conditions
Prosthetic-joint Infection, Dysbiosis
Interventions
Probiotic, Standard of care
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Patient Decision Aids, Congenital Heart Disease, Congenital Heart Defect
Interventions
Decision Aid, Values Clarification Exercise
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
EN3285, Placebo, Standard of care
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Houston, Texas
Conditions
Cesarean Section Complications
Interventions
Ibuprofen, acetaminophen, oxycodone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
COPD
Interventions
Best available care (BAC), Telerehabilitation (TH)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
DKA
Interventions
Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Catheter-related Infections
Interventions
Mino-Lok, Antibiotic lock
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Hines, Illinois + 16 more
Conditions
Emphysema
Interventions
RePneu Lung Volume Reduction Coil System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
35 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 19 more
Conditions
Concussion, Brain, TBI, Depression, Anxiety
Interventions
Collaborative Care
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
AF - Atrial Fibrillation, Complication, Atrio-Esophageal Fistula
Interventions
ensoETM. Esophageal cooling during AF ablation, Esophageal temperature monitoring probe
Device
Lead sponsor
Advanced Cooling Therapy LLC, d/b/a Attune Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Naples, Florida • Overland Park, Kansas • Boston, Massachusetts + 2 more
Conditions
Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions
Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
Other
Lead sponsor
Proove Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
Conditions
Necrotizing Fascitis
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Conditions
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Interventions
ChemoID Assay, Standard Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina